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Mutations of the p53 tumour suppressor gene are associated with
tumorigenesis of most types of human cancers including ovarian
cancer (Hollstein et al, 1991; Harris and Hollstein, 1993; Wen
et al, 1999). Mutational inactivation of the p53 gene leading to an
altered p53 protein occurs during tumorigenesis of approximately
50% of ovarian cancers (Marks et al, 1991; Milner et al, 1993;
Wen et al, 1999). These alterations represent in more than 90%
point missense mutations in the highly conserved core region
resulting in a functionally inactive mutant protein (Soussi and
May, 1996). The mutation frequently causes a delayed turnover of
the protein and thereby an extended half-life compared to the wild-
type protein. It accumulates in the tumour cell nucleus to high
levels detectable by immunohistochemical methods (Lane, 1992;
Legros et al, 1994; Runnebaum et al, 1996). Mutant p53 protein
was shown to be immunogenic in different species leading to
generation of autoantibodies (p53 AAb). These antibodies were
directed against the immunodominant linear epitopes located in
the amino- and carboxy-terminal regions of p53 (Schlichtholz
et al, 1992; 1994; Lubin et al, 1993; Legros et al, 1994; Soussi and
May, 1996).
p53 AAb were first detected in patients with breast cancer
(Crawford et al, 1982), and in children with a variety of malignan-
cies (Caron de Fromentel et al, 1987). Ovarian cancers were
among the most immunogenic malignancies inducing p53 AAb
response. In a comparative study, patients with cancer of the lung,
breast, ovary or colon showed the highest p53 AAb prevalence
(Angelopoulou et al, 1994).
Early investigations used electrophoresis-based systems such as
Western blot analysis or immunoprecipitation applicable to only
small patient samples (Crawford et al, 1982; Caron de Fromentel
et al, 1987). The development of ELISA systems allowed for rapid
and facilitated analysis of larger patient series, particularly to
study the diagnostic and prognostic value of p53 AAb (Lubin et al,
1995; Angelopoulou et al, 1997). However, it has been hypothe-
sized that the specificity of the early assay systems may have been
limited due to single-step purification of the antigen p53 allowing
binding of unspecific antibodies to epitopes exposed by p53
protein denaturation or to fragments of other proteins.
In the present study, an ELISA was developed based on double-
purified and renatured, recombinant human p53 protein (Nedbal
et al, 1997). Using this new assay, we assessed the prevalence of
p53 AAb in preoperative patients with benign, borderline or
malignant adnexal mass and the relation to histopathological and
clinical parameters, particularly the clinical outcome. Implications
for clinical management of patients with suspicious adnexal mass
are discussed.
METHODS
Patients and materials
In this retrospective cohort study, we included 245 Caucasian
women, 128 of whom were newly diagnosed with ovarian malig-
nancy. One-hundred and seventeen patients (age range: 17–94
years, median 49 years) who were operated for benign lesions of
the ovaries served as controls. Patients were enrolled at the
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Diagnoses were proven histologically. Cases and controls were
included on the basis of availability of pre-treatment serum
samples. Serum had been obtained by centrifugation and was
stored at –80°C until analysis. One hundred and thirteen women
aged between 21 years and 89 years (median 61 years) had
primary invasive ovarian cancer. Fifteen patients (age range:
23–75 years, median 50 years) were diagnosed with borderline
lesions of the ovaries. Patients with borderline tumours were
initially treated by oophorectomy. Patients with invasive cancer
underwent cytoreductive surgery followed by chemotherapy. They
were postoperatively staged according to the classification of the
International Federation of Gynaecologists and Obstetricians
(FIGO). Where complete surgical cytoreduction could not be
achieved, the presence of visible residual tumour was recorded.
Forty-five patients had visible tumour residues, 40 patients were
resected R0 (information missing on 28). Platinum-based
chemotherapy was given to 76 of 113 (67%) of the patients.
Thirteen patients with stage I disease received no adjuvant therapy.
Eighteen patients with stage III or IV received chemotherapy not
containing platinum. Three patients with stage II and stage
III disease refused chemotherapy. Another three patients with
progressive disease underwent surgery, but died due to poor
general condition before chemotherapeutical treatment could be
started. Clinical data were obtained from the patients’ charts and
the histopathological reports. Values of the tumour marker CA125
were routinely determined at admission. Values below 35 U ml–1
were considered normal. CA125 test results were available for 106
cancer cases and 112 controls with benign lesions. Patients with
invasive cancer were followed up with respect to relapse and
survival until November 30, 1998. Patients with borderline lesions
and those with benign tumours were screened only for the pres-
ence of serum p53 AAb and excluded from further analysis.
ELISA
The ELISA was based on double-purified recombinant human
wild-type p53 protein (Nedbal et al, 1997). In brief, p53 was
expressed in E. coli tagged aminoterminally with His6 and purified
through metal chelate affinity chromatography under denaturing
conditions (8 M urea). The denatured p53 protein was refolded by
stepwise removal of urea in a dialysis procedure and further puri-
fied through gel permeation (Sephadex 200, Pharmacia, Erlangen,
Germany). Integrity of refolded p53 was confirmed with the
monoclonal antibody PAb 421 recognizing wild-type p53 binding
sequence-specifically to a 20 bp oligodeoxyribonucleotide
(5¢ GGACATGCCCGGGCATGTCC-3¢). Microtitre plates (Maxi-
sorp, Nunc, Wiesbaden, Germany) were coated with 50 ml per well
of double-purified p53 (0.2 mg ml–1) in PBSI. Plates were incu-
bated overnight at 4°C and blocked for 1 h at 37°C in 5% non-fat
milk powder (Merck, Darmstadt, Germany) in PBS. Serum was
diluted 1:100 and incubated for 1 h at 37°C. After washing with
PBS/0.05% Tween 20, peroxidase-conjugated goat antiserum to
human immunoglobulin (Dianova, Hamburg, Germany) was
added and incubated at 37°C for 30 min. Bound antibody was
detected with tetramethylbenzidine and the results monitored in an
automatic microtitre plate reader. ELISA cut-off was defined as
duplicate of the mean of the absorption using sera from 100
healthy blood donors without a history of cancer. Cut-off
corresponded to an antibody titre of 15 binding units. For
measuring the antibody titre the assay was standardized using a
positive human serum (positive standard) at ample supply showing
no change of titre during storage. Binding activity of 1:600 diluted
positive standard was defined as 1 binding unit. The binding
activity showed linearity over a broad range with 1 binding unit
lying in the middle of the linear line. Internal standard curve was
used for calculation of the corresponding binding units of the
human sera tested. Positive sera were diluted in a range from 1:100
to 1:100 000 to keep the analysis in the linear range of the standard
curve. All samples were assayed in duplicate and all quantitative
values were means of duplicate determinations. The analyst was
unaware of any clinical patient data.
Western blot
For confirmation of ELISA test results Western blots were
performed. The amount of purified p53 protein loaded on a minigel
was 0.3 mg lane–1, which converts into 5 mg cm–2 on the membrane.
The sera were tested in a dilution of 1:100. Bound antibodies 
were detected with alkaline phosphatase-coupled goat anti-human
antibodies and colour developed using bromo-chloro-indolyl
phosphate/nitroblue tetrazolium (BCIP/NBT).
Immunohistochemistry of p53 protein in tumour tissue
Results of routine immunohistochemical (IHC) staining of p53 in
tumour tissue were available from 56 patients. Tissue sections 
(7 mm) were taken from paraffin-embedded ovarian tumour speci-
mens, mounted on glass slides, and stained by the avidin biotin
immunoperoxidase method using the anti-human p53 mouse
monoclonal antibody DO-1 (Dianova). Immunoreactivity was
assessed recording proportion of stained cells and staining inten-
sity. Percentages of positive cells were scored 1 for 0–10%, 2 for
10–50% and 3 for > 50%. Tissue sections containing 10% or more
stained tumour cells were considered as IHC-positive. Evaluations
were independently performed by two pathologists of the insti-
tution.
Statistical analysis
For patients with invasive ovarian cancer, Fisher’s exact test was
applied to test for an association of p53 AAb with each of the
following dichotomized study parameters: Age (< 50 years vs ³ 50
years), menopausal status (premenopausal vs postmenopausal),
oestrogen and progesterone receptor status (IRS ≤ 3 vs IRS > 3;
immuno-reactive score, score for staining intensity ´ score for
percentage of positive cells), tumour cell type (serous vs other than
serous), and presence of lymph-node metastases at primary
surgery (present vs absent). In some cases information on partic-
ular parameters was not available.
Cochran-Armitage trend test was conducted across the polyto-
mous variables tumour stage (FIGO), grading, and immunohisto-
chemical results on p53. Our hypothesis was that the frequency of
p53 AAb would be higher in patients with advanced tumour stages
or less differentiated tumours. We also expected that the immune
response to p53 would depend on the grade of p53 overexpression
in tumour cells as assessed by the proportion of IHC-stained cells
and staining intensity. Therefore P-values of the trend test were
calculated one-sided.
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death, loss to follow-up or end of the follow-up period. Patients
were stratified by presence or absence of p53 AAb. Kaplan–Meier
curves were calculated for relapse-free interval and overall
survival time. Differences between the Kaplan–Meier curves were
evaluated by the log-rank test. Separately, the p53 AAb titre was
considered as a predictive variable for survival. Starting at median
(424 units) and then cutting at each value above and below until
significance was obtained, a cut-off value was empirically
selected. The level of significance was set to 0.05. All data
analyses were carried out using SAS software (SAS Institute Inc,
Cary NC, USA).
RESULTS
Descriptive characteristics of the 113 ovarian cancer patients eval-
uated in the study are shown in Table 1. The prevalence of p53
AAb as detected with the described ELISA in the ovarian cancer
patients at the time of diagnosis was 18.6% (21 of 113). In these
patients titres ranged from 20 units to 51 400 units. Median was
424 units. Two patients had excessively high titres of 23 600 units
and 51 400 units. The specificity of our p53 AAb ELISA was
99.2%. The assay showed a positive reaction only for one out of
117 patients in the control group, who had a titre of 34 units (mean
of three independent duplicate measurements). The histology
diagnosis of this patient was a unilateral benign cystadenoma
simplex. p53 immunohistochemical analysis specifically
performed on this material was negative. This patient with a severe
type 1 diabetes mellitus was followed-up for 3 years without
evidence of malignancy. Positivity for p53 AAb in the ELISA was
confirmed by Western blot. All sera with an antibody titre higher
than 30 units were clearly detectable in Western blot analysis.
Some sera with a lower titre produced only a faint signal in
Western blot analysis, possibly due to a lower sensitivity of this
assay. None of the 15 patients with borderline lesions had serum
p53 AAb detectable by ELISA or Western blot analysis. In terms
of its use as a diagnostic test for malignancy, the likelihood ratio
for a positive test result in the ELISA was 21.7; the likelihood ratio
for a negative result was 0.8. For comparison, the sensitivity of the
CA125 test was 84.9% with specificity 76.8%, likelihood ratios
were 3.7 for a positive result and 0.2 for a negative result.
Table 1 shows the presence of p53 AAb in relation to clinico-
pathological parameters. In patients with FIGO stage I and II
disease, three of 36 (8%) had p53 AAb in their serum. The
frequency of p53 AAb was positively related with tumour stage,
showing a higher prevalence in the advanced stages FIGO III and
IV (14 of 62, 23% and four of 15, 27%, respectively; one-sided
trend test over all stages: P = 0.034). Likewise, presence of p53
AAb was related with grade of tumour cell differentiation (one-
sided trend test: P = 0.009). The presence of p53 AAb was
independent of the menopausal status of the patient and immuno-
histochemically determined hormone receptor status. p53 AAb
were not associated with particular histologic cell types of the
tumour nor lymph-node involvement.
Patients were followed-up for a median time of 22 months
(range: 1–68 months). Mortality during follow-up was signifi-
cantly higher in the p53 AAb-positive group than in the p53 AAb-
negative group (71% vs 32%, P = 0.001). Kaplan–Meier analysis
revealed that patients with p53 AAb died significantly earlier
(Figure 1, P = 0.002). The curves were nearly identical during the
first 12 months of follow-up. One year survival rates were 
85% and 84%, respectively. Thereafter, the graph for the p53 
AAb-positive group decreased rapidly. Survival rates at 24 months
were 68% and 39%, survival rates at 36 months were 61% and 19%
for the AAb-negative and the AAb-positive  group, respectively.
We separately studied variables previously identified to be
predictors of poor outcome in ovarian cancer (stage of disease,
tumour grading, residual tumour after surgery). Log-rank test
confirmed for our cohort that patients were at higher risk of earlier
death when having advanced FIGO III and IV stage (P = 0.0002),
high tumour grading (P = 0.0003), or residual tumour after surgery
(P = 0.0007). To investigate whether p53 AAb was an independent
predictor, we repeated the analysis and adjusted for these vari-
ables. Survival was still significantly different by p53 AAb status
after adjusting for tumour stage (P = 0.026), grading (P = 0.029)
and presence or absence of residual tumour (P = 0.005).
Differences in survival curves of p53 AAb-positive and p53 AAb-
negative patients were also significant (P = 0.030) when 
only patients treated with platinum-based chemotherapy were
considered (plots not shown).
Figure 2 shows the Kaplan–Meier curves with relapse as the
end-point of follow-up. Patients with detectable p53 AAb had a
shorter relapse-free survival time. The difference was of border-
line significance (P = 0.055).
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Table 1 Characteristics of ovarian cancer patients and association of p53
AAb with clinicopathological parameters (Fisher’s exact test). Given is the
number and percentage of patients with positive result in the ELISA relative
to the total number
Feature n % P-value
Age (years)
< 50 2/26 8
³ 50 19/87 22 0.151
Menopausal status
premenopausal 2/23 9
postmenopausal 15/73 21 0.346
Oestrogen receptor:
negative (IRS ≤ 3) 13/70 19
positive (IRS > 3) 4/24 17 1.000
Progesterone receptor
negative (IRS ≤ 3) 14/77 18
positive (IRS > 3) 3/17 18 1.000
Stage (FIGO)
I 2/23 9
II 1/13 8
III 14/62 23
IV 4/15 27 0.034a
Grading
1 1/13 8
2 4/41 10
3 16/57 28 0.009a
Tumour cell type
serous 12/68 18
other than serous 9/45 20 1.000
Lymph-node metastasis
yes 4/26 15
no 12/74 16 1.000
Relapse
No 9/61 15
Yes 12/49 24 0.228
Death
No 6/68 9
Yes 15/44 34 0.001
aTrend test, one-sided P-valueComparing survival in relation to antibody level within the p53
AAb-positive patients, a significant difference was obtained with
the cut-off value set to 250 units, which corresponds to the lower
tertil in that sample. Survival was shorter for patients whose p53
AAb titres lay above this value (P = 0.027). The median survival
times in these two groups were 17 and 34 months, respectively.
p53 AAb were detected only in sera of patients with tumours
containing 10% or more cells immunohistochemically positive for
nuclear p53 overexpression (P = 0.006). Table 2 shows the
frequencies of serum p53 AAb in relation to the proportion of
immunohistochemically positive-stained cells. No p53 AAb were
detectable when IHC was negative, whereas p53 AAb were
present in 36% of patients whose tumours had more than half of
the cells stained positive. The trend test confirmed our hypothesis
of a positive association of p53 AAb frequency with the proportion
of IHC-stained cells (P = 0.002). No association was found
between p53 AAb and the staining intensity. p53 AAb were not
detectable in 26 of 38 (68%) patients whose tumours showed p53
protein overexpression in tissue. Within this group, 18 of 28 (64%)
of patients with more than 50% of cells positive for p53 by IHC
had a negative antibody test.
DISCUSSION
Based on our newly developed ELISA, we found p53 AAb in 21 of
113 (19%) ovarian cancer patients with a specificity of 99%
for invasive ovarian cancer. All ELISA-positive samples were
confirmed by positive Western blot analysis. The one false-
positive sample was taken from a patient with severe diabetes
mellitus possibly with an immunological cross-reactivity against
various nuclear proteins including p53. Previously reported preva-
lences of p53 AAb in ovarian cancer ranged from 15%
(Angelopoulou et al, 1994) to 46% (Vogl et al, 1999). The preva-
lence of 19% in our cohort of ovarian cancer patients is compa-
rable to that of other epithelial cancers, particularly colorectal
cancer with an antibody frequency between 16% and 23%
(Angelopoulou et al, 1994; 1997), breast cancer with reported p53
AAb frequencies between 9% and 15% (Schlichtholz et al, 1992;
Crawford et al, 1982) and lung cancer with frequencies between
8% and 24% (Lai et al, 1998, Schlichtholz, 1994).
Prevalences in previous reports appeared to depend on the type
of assay used. In ovarian cancer, higher prevalences were found
when ELISAs were used for detection (Green et al, 1995;
Gadducci et al, 1996; 1998; Vogl et al, 1999). In these studies,
ELISA results were not validated by other assay techniques and no
control groups were tested, raising questions about the specificity
of these assays. In a comparative analysis of three ELISA systems
recently published by others, our solid-phase ELISA using double-
purified and renatured wild-type p53 protein provided the highest
diagnostic accuracy in correctly identifying cancer cases from a
cohort of cases and controls (Rohayem et al, 1999). The other two
test systems were a solid-phase ELISA using eucaryotically
expressed wild-type p53 and a two-site sandwich ELISA using
native p53 extracts from tumour cells.
Presence of p53 AAb positively correlated with tumour grading
(P = 0.009) and stage (P = 0.034), indicating an aggressive behav-
iour of p53-AAb-inducing ovarian cancers. Tumour aggressive-
ness was also reflected by the shortened survival time and
relapse-free period of antibody carriers. There are only few data on
the prognostic value of p53 AAb in ovarian cancer. Angelopoulou
et al found in bivariate analysis a significantly increased risk only
for relapse (Angelopoulou et al, 1996). In multivariate analysis,
however, p53 AAb was not an independent prognostic factor.
Gadducci et al found that progression-free survival and overall
survival of advanced (FIGO III and IV) ovarian cancer patients
were not related to preoperative serum p53 AAb status (Gadducci
p53 autoantibodies and prognosis in ovarian cancer 1341
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Fig. 1: Overall survival time in ovarian cancer patients by presence of
p53AAb.
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Fig. 2: Relapse-free survival time in ovarian cancer patients by presence of
p53AAb.
Table 2 Serum p53 AAb and p53 immunohistochemistry
p53 AAb statusb
PPa Positive Negative Total
0–10% 0 (0)b 18 (100) 18
10–50% 2 (20) 8 (80) 10
> 50% 10 (36) 18 (64) 28
Total 12 (21) 44 (79) 56
aProportion of positive-stained cells; bNumber of patients (%);
Statistic: trend test (P = 0.002, one-sided)et al, 1999). The data based on our newly developed ELISA
clearly attribute a prognostic value to p53 AAb. Presence of p53
AAb was still an independent predictor of worse clinical outcome
even after adjusting for the well-established prognostic parame-
ters. The association of poor overall survival with p53 AAb as
detected by our ELISA was unequivocally more clear-cut than the
association with p53 mutation in the tumour and/or p53 IHC
reported in previous studies including ours. Particularly in multi-
variate analyses, p53 IHC was not an independent predictor
of poor survival (Eltabbakh et al, 1997; Wen et al, 1999).
Quantitation of p53 AAb titre generated additional predictive
information on patients’ outcome. Our results favourably compare
with studies on breast cancer and lung cancer showing a positive
p53 AAb status to be an independent prognostic variable for poor
overall survival (Peyrat et al, 1995; Lai et al, 1998).
Prognosis of patients with invasive ovarian cancer has changed
little over the past two decades. Although early-stage ovarian
cancer is highly curable, more than two thirds of the patients
present with advanced disease with a poor survival rate.
Transvaginal sonography (TVS) – in general of low specificity
– has been demonstrated to be a valuable screening technique with
a relatively high sensitivity for early-stage ovarian cancer in high-
risk populations of asymptomatic women (DePriest et al, 1997).
Tumour marker CA125 determination (sensitivity 84.9%, speci-
ficity 76.8% in the present study) has failed to compensate for the
lack of specificity of TVS. Owing to its high specificity (99%) for
malignancy, the p53 AAb ELISA is suitable to be employed in a
two-stage procedure as confirmatory test on individuals who had a
positive or suspicious screening test. In this case, the high likeli-
hood ratio for a positive result of 21.7 of the p53 AAb ELISA
provokes a conclusive change from pre-test to post-test probability
of malignancy. Future prospective studies should test whether p53
AAb ELISA can help to increase the diagnostic accuracy of ultra-
sound in order to avoid the delay of operation on ovarian cancer
patients with low morphologic suspicion index. A positive p53
AAb test result in patients with adnexal mass should prompt
referral to a centre with an infrastructure allowing explorative
laparotomy. If laparoscopy is initially performed, availability of
immediate and accurate pathologic diagnosis in such a centre is an
important prerequisite for the treatment of these patients (Dottino
et al, 1999).
Mechanisms leading to p53 immunogenicity still remain unex-
plained. Several studies consistently demonstrated that most anti-
bodies preferentially target immunodominant linear epitopes
contained in the amino (residues 1–95) and carboxy (residues
300–393) termini of p53. Both are exposed to the immune system
due to their location on the surface of the protein, while the core
domain prone to mutations is buried in the molecule (Schlichtholz
et al, 1992; 1994; Legros et al, 1993; 1994; Lubin et al, 1993).
These observations suggested that the specific immune response
could be triggered by the level of nuclear p53 expression (Soussi
and May, 1996). Our data on ovarian cancer support this hypoth-
esis. All patients with circulating p53 AAb showed positive
tumour immunostaining indicating p53 accumulation (P = 0.006).
Such an association has also been reported for breast cancer
(Mudenda et al, 1994) and colorectal cancer (Houbiers et al,
1995). Additionally, we found that the frequency of p53 AAb was
positively related (P = 0.002) to the proportion of stained tumour
cells, indicating an underlying quantitative effect on antibody
induction. Only a subset of patients with IHC-positive tumours
had a positive result in our ELISA, suggesting that p53 accumula-
tion in ovarian cancer is not sufficient to induce a detectable
humoral response.
In summary, p53 AAb, as detected by double-purified and
refolded p53 antigen, were highly specific for malignancy in
patients with ovarian mass and correlated with aggressive behav-
iour of the cancer. Presence of p53 AAb independently predicted
poor clinical outcome, particularly above a cut-off value of 250
units. Quantitation of p53 AAb might contribute additional prog-
nostic information. Further studies may prove the p53 AAb ELISA
to be a valuable tool to preoperatively identify patients with
aggressive ovarian tumours. p53 AAb testing could improve diag-
nostic accuracy of screening methods and consequently reduce
stage at detection, decrease stage-specific mortality and could help
in clinical decision-making on therapeutic regimens such as adju-
vant p53 gene replacement therapy in addition to standard
chemotherapy.
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